# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price ...
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA des...
HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price ...
RBC Capital analyst Luca Issi reiterates Caribou Biosciences (NASDAQ:CRBU) with a Outperform and maintains $14 price target.
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $...